117 related articles for article (PubMed ID: 37272883)
1. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept.
Khaparkhuntikar K; Maji I; Gupta SK; Mahajan S; Aalhate M; Sriram A; Gupta U; Guru SK; Kulkarni P; Singh PK
J Biomol Struct Dyn; 2024; 42(3):1469-1484. PubMed ID: 37272883
[TBL] [Abstract][Full Text] [Related]
2.
Muthiah I; Rajendran K; Dhanaraj P; Vallinayagam S
J Biomol Struct Dyn; 2021 Aug; 39(13):4807-4815. PubMed ID: 32580684
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR, molecular dynamics simulations and molecular docking studies of benzoxazepine moiety as mTOR inhibitor for the treatment of lung cancer.
Chaube U; Chhatbar D; Bhatt H
Bioorg Med Chem Lett; 2016 Feb; 26(3):864-874. PubMed ID: 26764189
[TBL] [Abstract][Full Text] [Related]
4.
Sain A; Kandasamy T; Naskar D
J Biomol Struct Dyn; 2022; 40(21):10962-10977. PubMed ID: 34296655
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
6. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive molecular docking and dynamic simulations for drug repurposing of clinical drugs against multiple cancer kinase targets.
Shaikh N; Linthoi RK; Swamy KV; Karthikeyan M; Vyas R
J Biomol Struct Dyn; 2023; 41(16):7735-7743. PubMed ID: 36134605
[TBL] [Abstract][Full Text] [Related]
8. Exploring novel and potent molecules for disrupting DEPTOR-mTOR interaction through structure-steered screening, extra-exactitude molecular docking, prime binding free energy estimation and voguish molecular dynamics.
Shah BA; Ganai SA; Koul AM; Mohan S; Amin A; Wani Z; Majeed U; Rajamanikandan S; Farooq F; Malik FA; Shah NN; Qadri RA
J Biomol Struct Dyn; 2022; 40(22):12037-12047. PubMed ID: 34431457
[TBL] [Abstract][Full Text] [Related]
9. Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach.
Kumar BH; Manandhar S; Choudhary SS; Priya K; Gujaran TV; Mehta CH; Nayak UY; Pai KSR
Mol Divers; 2023 Oct; 27(5):2015-2036. PubMed ID: 36244040
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer.
Purawarga Matada GS; Dhiwar PS; Abbas N; Singh E; Ghara A; Das A; Bhargava SV
J Biomol Struct Dyn; 2022 Aug; 40(13):6183-6192. PubMed ID: 33525984
[TBL] [Abstract][Full Text] [Related]
11. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
12. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
13. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Mohammadnejadi E; Razzaghi-Asl N
J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
[TBL] [Abstract][Full Text] [Related]
14.
El-Hddad S; Sobhy M; Ayoub A; El-Adl K
J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
[TBL] [Abstract][Full Text] [Related]
15. Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: an in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
Mol Divers; 2023 Oct; 27(5):2273-2296. PubMed ID: 36318405
[TBL] [Abstract][Full Text] [Related]
16. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
17.
Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
[TBL] [Abstract][Full Text] [Related]
18. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
J Mol Model; 2021 Dec; 28(1):17. PubMed ID: 34962586
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
[TBL] [Abstract][Full Text] [Related]
20. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
